Ofloxacin Tablets

Published Online: Monday, March 1, 2004

Teva Pharmaceuticals USA (North Wales, Pa) recently announced the introduction and availability of Ofloxacin Tablets. This product is AB-rated and is bioequivalent to Ortho-McNeil?s Floxin tablets. The product is prescribed to patients to reduce the development of drug-resistant bacteria and to maintain the effectiveness of this and other antibacterial drugs. Ofloxacin Tablets are indicated for the treatment of adults with mild-to-moderate infections (unless otherwise indicated) caused by susceptible strains of designated microorganisms. These infections include chronic bronchitis, community-acquired pneumonia, and acute pelvic inflammatory disease, among others. Ofloxacin Tablets 200, 300, and 400 mg are available in bottle sizes of 100. For more information, visit www.tevapharmusa.com.

Latest Articles
This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings and more.
Chronic kidney disease incidence has grown faster than many of its common comorbidities such as diabetes and hypertension, and medications may be an underappreciated driver of this growth.
President Barack Obama’s fiscal year 2017 budget proposal calls for an additional $1.1 billion to combat the nation’s spiraling opioid epidemic.
Baxter International is voluntarily recalling intravenous solution due to leaking containers and the potential for particulate matter.
Latest Issues